Profile of Cytostatic Drug Use in Breast Cancer Patients (Mammae carcinoma) at Medan Hospital
https://doi.org/10.33860/jik.v17i3.2966
Keywords:
Cytostatic Drugs, Chemotherapy, Breast CancerAbstract
Breast cancer is the most common type of cancer in the world (2,261,419 cases) and in Indonesia (65,858 cases). This research aims to determine the class and type of cytostatic drugs most frequently used in breast cancer chemotherapy patients from January to March 2023 at RSUP Haji Adam Malik Medan. This study used a descriptive survey method with a saturated sample of 176 medical records. Data collection was done retrospectively by gathering information from the electronic medical records of the patients. The research results show that the characteristics of the patients are as follows: the majority were female, totalling 176 patients (100%). The most common age group was 45-54 years, with 111 patients (63.1%), and the prescription of cytostatic drugs was highest in March, with 80 patients (36.9%). In conclusion, the most commonly used class of cytostatic drugs was antibiotics, with 146 cases (32.88%), and the most commonly used type of cytostatic drug was Doxorubicin, with 114 cases (25.68%). This indicates that the use of antibiotics is a significant part of breast cancer treatment, and it is important to pay attention to the safety and regularity of drug use to prevent drug resistance and the severity of the disease.
References
Juwita DA, Almahdy A, Afdila R. Penilaian Kualitas Hidup Terkait Kesehatan Pasien Kanker Payudara di RSUP Dr. M. Djamil Padang, Indonesia. Jurnal Ilmu Kefarmasian Indonesia. 2019 Apr 24;17(1):114-9.
Taqwin T., Sumiaty S., Lasman K. Penyuluhan, Pengetahuan Dan Sikap Pasangan Usia Subur Tentang Inpeksi Visual Asam Asetat (Iva) Di Kelurahan Birobuli. Poltekita: Jurnal Ilmu Kesehatan. 2018;12(1):8-14.
Sari YO, Rustini R, Diana D, Hapsari TD. Audit secara prospektif terhadap antimicrobial stewardship program pada pasien kanker payudara di RSUP Dr. M. Djamil Padang. Jurnal Sains Farmasi & Klinis. 2017 Dec 15;4(1):88-96. https://doi.org/10.29208/jsfk.2017.4.1.204
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer. 2019 Apr 15;144(8):1941-53.
Haryani S. Evaluasi Penggunaan Obat Kemoterapi Pada Pasien Kanker Payudara Di RSUP Fatmawati Periode Februari 2021. Jurnal Farmasi Klinik Base Practice. 2022 Dec 12;1(1):50-60.
WHO. Cancer in Indonesia. Int Agency Res cancer [Internet]. 2020;1(1):1–2. Available from: https://gco.iarc.fr/today/fact-sheets-cancers
Kementerian Kesehatan RI. Laporan Nasional RISKESDAS 2018 [Internet]. Jakarta: Kementerian Kesehatan RI; 2019 [cited 2021 Mar 21]. Available from: moz-extension://2f8f5aff-2efc-4374-8889-d02c680902af/enhanced-reader.html?openApp&pdf=http%3A%2F%2Flabdata.litbang.kemkes.go.id%2Fimages%2Fdownload%2Flaporan%2FRKD%2F2018%2FLaporan_Nasional_RKD2018_FINAL.pdf
Kusumawaty J, Noviati E, Sukmawati I, Srinayanti Y, Rahayu Y. Efektivitas Edukasi SADARI (Pemeriksaan Payudara Sendiri) Untuk Deteksi Dini Kanker Payudara. ABDIMAS: Jurnal Pengabdian Masyarakat. 2021;4(1):496-501.
Elmika E, Adi MS. Gambaran Umur, dan Jenis Kelamin Pasien Kanker Payudara di RS Ibnu Sina Kota Makassar. Jurnal Penelitian Kesehatan" SUARA FORIKES"(Journal of Health Research" Forikes Voice"). 2020 Jun 11;11(4):422-4.
Malau J, Rivianto FA, Khairunnisa S, Nuriah S, Rahayu S, Amelia TC, Verliani H, Mulki MA. Artikel Review: Kajian Molekuler Obat Pada Kanker Payudara. Jurnal Pendidikan dan Konseling (JPDK). 2022 Dec 13;4(6):11032-41.
Fajar IM, Heriady Y, Aji HW. Karakteristik Usia, Gambaran Klinis dan Histopatologi Pasien Kanker Payudara di RSUD Al-Ihsan Provinsi Jawa Barat Periode Januari 2018-Oktober 2020. Jurnal Riset Kedokteran. 2021 Dec 31:85-91.
Arisanti JP, Saptarina N, Andarini YD. Evaluasi penggunaan obat kemoterapi pada penderita kanker payudara di RSUP dr. Seoradji Tirtonegoro periode 2018. Pharmasipha. 2020 Sep 5;4(2):1-8.
Sulistyoningtyas S, Dwihestie LK. Jurnal Ilmiah Permas: Jurnal Ilmiah STIKES Kendal. Peran Mikronutrisi Sebagai Upaya Pencegah. Covid-19. 2022;12:75-82.
Megawati. Gambaran Ketahanan Hidup Lima Tahun Pasien Kanker Payudara Berdasarkan Karakteristik Demografi dan Faktor Klinis di Rumah Sakit Cipto Mangunkusumo Tahun 2007-2010. Skripsi. Univ Indones. 2012.
Sulaeman R, Irwansyah I, Sukmawati S, Masadah M. Riwayat Penggunaan Kontrasepsi Hormonal Pada Penderita Kanker Payudara. Jurnal Keperawatan Terpadu (Integrated Nursing Journal). 2021 Jun 21;3(1):10-6.
Elisya Y, Achmadi NK, Kurniawan D. Overview of Cytostatic Drug Prescribing for Inpatient Cancer Patients at RSUD Tarakan July-December 2021 Period. SANITAS: Jurnal Teknologi dan Seni Kesehatan. 2022 Dec 25;13(2):270-82.
Gao Y, Shang Q, Li W, Guo W, Stojadinovic A, Mannion C, Man YG, Chen T. Antibiotics for cancer treatment: A double-edged sword. Journal of Cancer. 2020;11(17):5135.
Saptowulan S, Maulina D. Gambaran Peresepan Kemoterapi Oral Pada Pasien Kanker Payudara di RS X di Jakarta Timur. Indonesian Journal of Health Science. 2023 Jul 18;3(2):136-41.
Agustini DD, Surahman E, Abdulah R. Quality of Life Patients with Breast Cancer Therapy Combination Fluorouracil, Doxorubicin, and Cyclofosfamide. Indonesian Journal of Clinical Pharmacy. 2015;4(3):175-85.
Chaikomon K, Chattong S, Chaiya T, Tiwawech D, Sritana-Anant Y, Sereemaspun A, Manotham K. Doxorubicin-conjugated dexamethasone induced MCF-7 apoptosis without entering the nucleus and able to overcome MDR-1-induced resistance. Drug design, development and therapy. 2018 Aug 1:2361-9.
Sebayang ANO. Efek Kardiotoksik Obat Kemoterapi Doxorubicin. JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia. 2019;7(1):1-5.
Zhao M, Ding XF, Shen JY, Zhang XP, Ding XW, Xu B. Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice. Journal of Zhejiang University. Science. B. 2017 Jan;18(1):15–26.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with Poltekita : Jurnal Ilmu Kesehatan agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
This work is licensed under a Creative Commons Attribution-ShareAlike 2.0 Generic License.
Poltekita : Jurnal Ilmu Kesehatan is licensed under a Creative Commons Attribution-Share Alike 4.0 International License
You are free to:
- Share, copy and redistribute the material in any medium or format
- Adapt, remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
